---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-035944"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2022-12-20T23:59:59+00:00"
generated_at: "2026-06-21T02:16:57.573271+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Oncotelic presents clinical data confirming TGF-β2 as target for gliomas; OS improvements shown

## Summary
- Reduced TGF-β2 increased OS from 9 to 22 mos in pediatric brainstem patients (N=95, p<0.0001).
- In glioma patients treated with TMZ, reduced TGF-β2 improved OS from 25 to 94 mos (N=230, p<0.0001).
- Similar OS improvement from 25 to 94 mos with radiation therapy (N=293, p<0.0001).
- Company states failure of GSK's bintrafusp alfa (TGF-β1 trap) validates focus on TGF-β2 isoform.
- Data presented at AACR-JCA Joint Conference Dec 10-14, 2022 in Maui.

## SEC filing metadata
- accession: 0001493152-22-035944
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2022-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315222035944/0001493152-22-035944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315222035944/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-035944
- JSON: https://secwatch.observer/filing/0001493152-22-035944.json
- Plain text: https://secwatch.observer/filing/0001493152-22-035944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.